Agilent Technologies

September 2025—Agilent Technologies is introducing three models to its Dako Omnis family of instruments—the Omnis 110, 165, and 165 Duo—designed to provide laboratories with the flexibility to tailor staining solutions according to volume, workflow, and diagnostic requirements. The Dako Omnis 110 is for low- to medium-volume labs and delivers up to 110 immunohistochemistry slides per day. The Dako Omnis 165 is engineered for medium-high volume labs and has a throughput of up to 165 IHC slides per day, and the 165 Duo has the capacity to run IHC and in situ hybridization slides. All models feature continuous, case-based processing and shared reagents. A newly integrated direct connection for deionized water and nonhazardous waste reduces handling time.

May 2025—Pathology plays a critical role in cancer care, encompassing the development of new treatments, diagnosis, staging, grading of disease, and clinical decision-making. While histopathological slides of tissue biopsies using hematoxylin and eosin staining and immunohistochemical staining remain central to this process, the rise of precision medicine testing is placing greater demands on pathology labs. Health care organizations globally are grappling with ways to address these challenges, mainly due to the declining number of individuals choosing pathology as a specialty. Additional challenges include the rising incidence of cancer, increased testing rates, and the growing complexity of testing. In this evolving landscape, artificial intelligence is emerging to revolutionize pathology, meeting these demands and improving patient outcomes.